FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
The CDRH Ombudsman, Les Weinstein, was appointed to this new position, located in the Office of the Center Director, in April, 2000. As an external Ombudsman, he investigates complaints from outside the agency, and facilitates the resolution of disputes between CDRH and the medical device industry it regulates. While providing this assistance, he maintains his impartiality and neutrality. A complaint is usually an expression of dissatisfaction, perhaps about timeliness, lack of communication, or an unhelpful employee. A dispute usually involves a disagreement with, a challenge to, or an appeal of a decision or action the Center has taken or is about to take. The Ombudsman also receives a wide variety of device related questions from the public of a scientific, regulatory, or procedural nature. This Report includes statistics on complaints, disputes, and questions as well as information on some other activities and initiatives the Ombudsman has undertaken. You may also wish to see his web site at http://www.fda.gov/cdrh/resolvingdisputes/ombudsman.html.
This Annual Report is the first one the Ombudsman is issuing for a full calendar year. His 2000 Annual Report covered only the initial nine months that he was in this position, but statistics from that Report are included below for limited comparison purposes.
Number Received:
2001 | 2000 (April - December) | |
---|---|---|
Complaints | 51 | 24 |
Disputes | 21 | 11 |
Total | 72 | 35 |
When Ombudsman was contacted: (If related to a process such as submissions.)
2001 | 2000 (April - December) | |
---|---|---|
As last resort | 17% | N/A |
Earlier | 60% | N/A |
Office: (Some involved more than one Office.)
2001 | 2000 | |
---|---|---|
ODE | 65% | 61% |
OC | 27% | 18% |
OSB | 3% | N/A |
OHIP | 3% | N/A |
OSM | 3% | N/A |
ODE by Division:
2001 | 2000 | |
---|---|---|
DRARD | 4% | 4% |
DCLD | 16% | 9% |
DGRND | 31% | 39% |
DDIGD | 12% | 22% |
DCRD | 22% | 26% |
DOED | 2% | 0% |
POS | 12% | N/A |
Subjects:
2001 | 2000 | |
---|---|---|
510(k) | 41% | 51% |
PMA | 9% | 6% |
Inspections | 8% | N/A |
IDE | 4% | N/A |
Imports | 4% | N/A |
Drugs of Abuse Tests | 4% | N/A |
Advertising/Promotion | 3% | N/A |
CLIA | 3% | N/A |
AIP | 3% | N/A |
Reuse | 1% | N/A |
Leveraging | 1% | N/A |
Recalls | 1% | N/A |
Petitions | 1% | N/A |
Registration/Listing | 1% | 6% |
Website | 1% | N/A |
FOI | 1% | N/A |
Other | 14% | 37% |
Issues by rank: (Some Complaints/Disputes involved more than issue.)
2001 | 2000 | |
---|---|---|
1. Evidence requirements (data, testing) to support a submission; "least burdensome" | 20% | 15%(2)* |
2. Policy/Procedures | 18% | 7% (4) |
3. Timeliness (of approval/clearance; setting up meetings; returning phone calls; etc.) | 17% | 13% (3) |
4. Miscommunication or lack of communication | 15% | 23% (1) |
5. Level playing field (concerns regarding unequal treatment) | 11% | 4% (8) |
6. Rude, difficult or unhelpful employees | 2% | 7% (5) |
7. Claims of conflict of interest, bias, retaliation | 2% | 7% (6) |
8. Jurisdiction over combination (drug/device) products | 1% |
3% (9) |
9. Disclosure (FOIA) | 1% | 5% (7) |
10. Allegations of employee incompetence | 0% | 3% (10) |
11. Other | 13% | 15% |
*Numbers in parentheses indicate ranking last year.
Status:
2001* | 2000 | |
---|---|---|
Pending at year's end | 36% | 37% |
Referred elsewhere | 12% | 11% |
Withdrawn | 13% | N/A |
Resolved | 39% | 51% |
*Includes 72 complaints/disputes received in 2001 and 13 pending at the end of 2000 and carried over to 2001.
Outcomes: (Of the complaints/disputes that were resolved.)
2001 | 2000 | |
---|---|---|
In favor of industry | 39% | 42% |
In favor of CDRH | 21% | 17% |
Mutual satisfaction | 39% | 41% |
Status and outcomes of complaints/disputes that involved evidence requirements as an issue:
2001 | 2000 | |
---|---|---|
Resolved | 54% | N/A |
In favor of industry | 27% | N/A |
In favor of CDRH | 47% | N/A |
Mutual satisfaction | 27% | N/A |
In addition to his involvement in complaints and disputes, the Ombudsman receives many device related questions from the public by phone, fax and email to which he responds, often in consultation with other CDRH offices, or refers to those offices for a direct reply.
2001 | 2000 | |
---|---|---|
Number Received | 101 | 29 |
From:
2001 | 2000 | |
---|---|---|
Industry | 56% | 41% |
Consumers | 25% | 28% |
Health care providers | 15% | 10% |
State government | 3% | N/A |
Media | 2% | N/A |
Academia | 1% | N/A |
Other | 0% | 21% |
Subjects: (Five most common.)
2001 | 2000 | |
---|---|---|
Status of submission | 10% | 14% |
IDE/human subjects | 9% | 14% |
Combination products | 9% | 10% |
Imports | 7% | N/A |
Labeling | 5% | 10% |
On July 2 the Guidance for industry and FDA, entitled "Resolving Scientific Disputes Concerning the Regulation of Medical Devices: a Guide to Use of the Medical Devices Dispute Resolution Panel," was issued in Final. This Guidance is available at http://www.fda.gov/cdrh/resolvingdisputes/1121.pdf.
The Ombudsman granted the first request for the newly created Medical Devices Dispute Resolution Panel to review a scientific dispute. The request was submitted by Lifecore Biomedical which was appealing a decision by CDRH that Lifecore's pre-market approval application (PMA) for Intergel Adhesion Prevention Solution was not approvable. The Panel meeting was held on September 6. The Panel voted unanimously to recommend that the PMA be approved. The Center Director subsequently concurred with this recommendation, and the PMA was approved. No other requests for review of a dispute by this Panel have been received.
As part of his Quality Assurance Manager role, the Ombudsman attends meetings that Center staff has with device firms and sponsors. Afterwards he surveys the industry participants to get feedback on the meeting. The Ombudsman also surveyed sponsors and applicants on their experiences specifically with Agreement and Determination Meetings and with Day 100 Meetings.
Updated 5/8/2002
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH